Endomembrane targeting of human OAS1 p46 augments antiviral activity
Frank Soveg(University of Washington), Ram Savan(University of Washington), Tien-Ying Hsiang(University of Washington), Jane H. Buckner(Virginia Mason Medical Center), Adriana Forero(University of Washington), J. Kenneth Baillie(Roslin Institute), Michael Gale(University of Minnesota), Eileen T. McAnarney(Texas Medical Center), Eric J. Allenspach(Center for Infectious Disease Research), Amy E.L. Stone(University of Colorado Denver), Nandan S. Gokhale(University of Washington), Karen Cerosaletti(Virginia Mason Medical Center), Shivam A. Zaver(University of Washington), Alison M. Kell(University of New Mexico), Saumendra N. Sarkar(Cleveland Clinic Lerner College of Medicine), Daniel B. Stetson(University of Washington), Chiraag Balu(University of Washington), Vineet D. Menachery(The University of Texas Medical Branch at Galveston), Justin A. Roby(Charles Sturt University), Uma Malhotra(Virginia Mason Medical Center), Joseph Pérez(UPMC Hillman Cancer Center), Joshua J. Woodward(University of Washington), Snehal Ozarkar(University of Washington), Katharina Esser‐Nobis(University of Washington), Cate Speake(Benaroya Research Institute), Johannes Schwerk(Helmholtz Centre for Infection Research), Erola Pairo‐Castineira(Roslin Institute), Jonathan M. Clingan(University of Washington), Julian R. Smith(University of Washington), Jennifer Hyde(University of Washington)
Cited by 80
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k